

Maria Chiara Bonini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2764571/publications.pdf>

Version: 2024-02-01

120
papers

12,551
citations

26630

56
h-index

25787

108
g-index

124
all docs

124
docs citations

124
times ranked

14697
citing authors

#	ARTICLE	IF	CITATIONS
1	Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. <i>Science Translational Medicine</i> , 2022, 14, eabg3072.	12.4	47
2	CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. <i>Science Translational Medicine</i> , 2022, 14, eabg8027.	12.4	21
3	CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	66
4	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
5	Workflow for high-dimensional flow cytometry analysis of T cells from tumor metastases. <i>Life Science Alliance</i> , 2022, 5, e202101316.	2.8	2
6	Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumab-treated MS patients. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1937-1943.	3.0	6
7	Enhancing anti-tumour efficacy with immunotherapy combinations. <i>Lancet, The</i> , 2021, 397, 1010-1022.	13.7	196
8	Flow cytometry data mining by cytoChain identifies determinants of exhaustion and stemness in TCR-engineered T cells. <i>European Journal of Immunology</i> , 2021, 51, 1992-2005.	2.9	10
9	Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia. <i>Nature Communications</i> , 2021, 12, 4844.	12.8	3
10	Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 776.e1-776.e13.	1.2	26
11	Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 772239.	4.8	18
12	Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. <i>Bone Marrow Transplantation</i> , 2020, 55, 126-136.	2.4	196
13	CD4+ Memory Stem T Cells Recognizing Citrullinated Epitopes Are Expanded in Patients With Rheumatoid Arthritis and Sensitive to Tumor Necrosis Factor Blockade. <i>Arthritis and Rheumatology</i> , 2020, 72, 565-575.	5.6	27
14	Overcoming key challenges in cancer immunotherapy with engineered T cells. <i>Current Opinion in Oncology</i> , 2020, 32, 398-407.	2.4	9
15	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. <i>Frontiers in Immunology</i> , 2020, 11, 1689.	4.8	63
16	Opportunities and challenges associated with the evaluation of chimeric antigen receptor T cells in real-life. <i>Current Opinion in Oncology</i> , 2020, 32, 427-433.	2.4	13
17	Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. <i>Frontiers in Immunology</i> , 2020, 11, 1217.	4.8	69
18	NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL. <i>Blood</i> , 2020, 136, 32-33.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	2.4	86
20	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nature Communications, 2019, 10, 1065.	12.8	120
21	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nature Medicine, 2019, 25, 603-611.	30.7	253
22	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplantation, 2019, 54, 1525-1552.	2.4	218
23	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
24	Beneficial role of CD8+ T-cell reconstitution after HLA-haploidentical stem cell transplantation for high-risk acute leukaemias: results from a clinico-biological EBMT registry study mostly in the T-cell-depleted setting. Bone Marrow Transplantation, 2019, 54, 867-876.	2.4	8
25	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	12.4	166
26	A ^{CD8^{hi}} Subset of ^{CD4⁺SLAMF7⁺} Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment. Arthritis and Rheumatology, 2018, 70, 1133-1143.	5.6	87
27	Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP. Bone Marrow Transplantation, 2018, 53, 1201-1205.	2.4	10
28	Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. Science Translational Medicine, 2018, 10, .	12.4	125
29	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 2018, 24, 282-291.	30.7	216
30	Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation. Cytotherapy, 2018, 20, 453-460.	0.7	14
31	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2018, 53, 722-728.	2.4	5
32	Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 1548-1552.	2.4	6
33	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2018, 53, 1139-1148.	2.4	117
34	Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nature Medicine, 2018, 24, 739-748.	30.7	947
35	Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene. Frontiers in Immunology, 2018, 9, 507.	4.8	73
36	Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2365-2370.	2.0	61

#	ARTICLE	IF	CITATIONS
37	NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. <i>Blood</i> , 2018, 131, 247-262.	1.4	164
38	T memory stem cells in health and disease. <i>Nature Medicine</i> , 2017, 23, 18-27.	30.7	396
39	Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. <i>American Journal of Hematology</i> , 2017, 92, 1011-1019.	4.1	14
40	NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. <i>Blood</i> , 2017, 130, 606-618.	1.4	71
41	Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. <i>Frontiers in Immunology</i> , 2017, 8, 1444.	4.8	62
42	Human Herpesvirus 6 Infection Following Haploidentical Transplantation: Immune Recovery and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2250-2255.	2.0	36
43	Impact of Immune Reconstitution (IR) and Graft-Versus-Host Disease (GvHD) on Clinical Outcomes after Treatment with Donor T Cells Transduced to Express the Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK cells) in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2016, 128, 4599-4599.	1.4	3
44	Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. <i>Blood</i> , 2015, 125, 2865-2874.	1.4	119
45	Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. <i>EMBO Molecular Medicine</i> , 2015, 7, 1513-1528.	6.9	146
46	Improving the safety of cell therapy with the TK-suicide gene. <i>Frontiers in Pharmacology</i> , 2015, 6, 95.	3.5	102
47	Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival. <i>Oncotarget</i> , 2015, 4, e1005460.	4.6	37
48	Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1506-1514.	2.0	121
49	Adoptive T cell therapy for cancer: The era of engineered T cells. <i>European Journal of Immunology</i> , 2015, 45, 2457-2469.	2.9	75
50	Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory. <i>Science Translational Medicine</i> , 2015, 7, 317ra198.	12.4	102
51	In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells. <i>Science Translational Medicine</i> , 2015, 7, 273ra13.	12.4	160
52	Cytokine-Induced Killer Cells Engineered with Exogenous T-Cell Receptors Directed Against Melanoma Antigens: Enhanced Efficacy of Effector Cells Endowed with a Double Mechanism of Tumor Recognition. <i>Human Gene Therapy</i> , 2015, 26, 220-231.	2.7	15
53	Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TK transduced T-cells. <i>Frontiers in Pharmacology</i> , 2015, 6, 76.	3.5	17
54	An Accelerated CD8+, but Not CD4+, T-Cell Reconstitution Associates with a More Favorable Outcome Following HLA-Haploidentical HSCT: Results from a Retrospective Study of the Cell Therapy and Immunobiology Working Party of the EBMT. <i>Blood</i> , 2015, 126, 1929-1929.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Standardized Long-Term Follow-up after Allogeneic Stem Cell Transplantation: A Cross-Sectional 1-Year Evaluation in 260 Adults. <i>Blood</i> , 2015, 126, 4362-4362.	1.4	0
56	Low-Dose Antithymocyte Globulin, Post-Transplant Cyclophosphamide and Sirolimus As Graft-Versus-Host Disease Prophylaxis in Unrelated Donor Transplants. <i>Blood</i> , 2015, 126, 5465-5465.	1.4	0
57	Tracking Genetically Engineered Lymphocytes Long-Term Reveals the Dynamics of T-Cell Immunological Memory. <i>Blood</i> , 2015, 126, 263-263.	1.4	0
58	Inflammation Converts Human Mesoangioblasts Into Targets of Alloreactive Immune Responses: Implications for Allogeneic Cell Therapy of DMD. <i>Molecular Therapy</i> , 2014, 22, 1342-1352.	8.2	20
59	Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. <i>Annals of Neurology</i> , 2014, 75, 447-453.	5.3	43
60	Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. <i>Immunological Reviews</i> , 2014, 257, 165-180.	6.0	46
61	Targeted genome editing in human repopulating haematopoietic stem cells. <i>Nature</i> , 2014, 510, 235-240.	27.8	517
62	A novel self-lipid antigen targets human T cells against CD1c+ leukemias. <i>Journal of Experimental Medicine</i> , 2014, 211, 1363-1377.	8.5	80
63	IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. <i>Blood</i> , 2013, 121, 573-584.	1.4	455
64	Lentivirus-Induced Dendritic Cells for Immunization Against High-Risk WT1 ⁺ Acute Myeloid Leukemia. <i>Human Gene Therapy</i> , 2013, 24, 220-237.	2.7	24
65	Graft-versus-leukemia Effect of HLA-haploidentical Central-memory T-cells Expanded With Leukemic APCs and Modified With a Suicide Gene. <i>Molecular Therapy</i> , 2013, 21, 466-475.	8.2	23
66	CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. <i>Blood</i> , 2013, 122, 3461-3472.	1.4	306
67	Trick to treat: tricking the thymus to treat cancer. <i>Blood</i> , 2013, 122, 304-306.	1.4	0
68	Predicting the Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: The Long and Winding Road toward Validated Immune Biomarkers. <i>Frontiers in Immunology</i> , 2013, 4, 71.	4.8	18
69	Off-Tumor Target Expression Levels Do Not Predict CAR-T Cell Killing: A Foundation For The Safety Of CD44v6-Targeted T Cells. <i>Blood</i> , 2013, 122, 142-142.	1.4	2
70	Use of TK-cells in haploidentical hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2012, 19, 427-433.	2.5	30
71	T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 120, 1820-1830.	1.4	47
72	Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT. <i>Blood</i> , 2012, 119, 4813-4815.	1.4	42

#	ARTICLE	IF	CITATIONS
73	A dual role for genetically modified lymphocytes in cancer immunotherapy. Trends in Molecular Medicine, 2012, 18, 193-200.	6.7	26
74	A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood, 2012, 119, 5697-5705.	1.4	437
75	Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nature Medicine, 2012, 18, 807-815.	30.7	398
76	When transgenes shape immunity: cancer immune gene therapy. Journal of Gene Medicine, 2012, 14, 384-385.	2.8	1
77	Early Reconstitution of T-Cell Immunity to CMV After HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is a Strong Surrogate Biomarker for Lower Non-Relapse Mortality Rates. Blood, 2012, 120, 4191-4191.	1.4	28
78	Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication. Blood, 2012, 120, 949-949.	1.4	3
79	Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nature Methods, 2011, 8, 861-869.	19.0	300
80	Genetic Modification of T Cells. Biology of Blood and Marrow Transplantation, 2011, 17, S15-S20.	2.0	30
81	IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. Blood, 2011, 117, 6469-6478.	1.4	40
82	Genetically Modified Donor Leukocyte Transfusion and Graft-Versus-Leukemia Effect After Allogeneic Stem Cell Transplantation. Human Gene Therapy, 2011, 22, 829-841.	2.7	25
83	TCR Gene Editing Results in Effective Immunotherapy of Leukemia without the Development of GvHD. Blood, 2011, 118, 667-667.	1.4	1
84	Clinical Impact of Suicide Gene Therapy in Allogeneic Hematopoietic Stem Cell Transplantation. Human Gene Therapy, 2010, 21, 241-250.	2.7	63
85	Concomitant Tumor and Minor Histocompatibility Antigen-Specific Immunity Initiate Rejection and Maintain Remission from Established Spontaneous Solid Tumors. Cancer Research, 2010, 70, 3505-3514.	0.9	25
86	High-Definition Mapping of Retroviral Integration Sites Defines the Fate of Allogeneic T Cells After Donor Lymphocyte Infusion. PLoS ONE, 2010, 5, e15688.	2.5	39
87	Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia.. Blood, 2010, 116, 3764-3764.	1.4	0
88	Transcriptional Enhancers Induce Insertional Gene Dereglulation Independently From the Vector Type and Design. Molecular Therapy, 2009, 17, 851-856.	8.2	79
89	Changes in T-Cell Responses Against Human Herpesvirus-8 Correlate with the Disease Course of latrogenic Kaposi's Sarcoma in a Patient with Undifferentiated Arthritis. Seminars in Arthritis and Rheumatism, 2009, 39, 170-175.	3.4	8
90	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. New England Journal of Medicine, 2009, 361, 478-488.	27.0	459

#	ARTICLE	IF	CITATIONS
91	Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase II study. <i>Lancet Oncology</i> , The, 2009, 10, 489-500.	10.7	458
92	IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. <i>Blood</i> , 2009, 113, 1006-1015.	1.4	153
93	The hidden (and lazy) TCR. <i>Blood</i> , 2009, 114, 2855-2856.	1.4	0
94	Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. <i>Blood</i> , 2008, 112, 3488-3499.	1.4	113
95	Changes in the Immune Responses Against Human Herpesvirus-8 in the Disease Course of Posttransplant Kaposi Sarcoma. <i>Transplantation</i> , 2008, 86, 738-744.	1.0	62
96	The Suicide Gene Therapy Challenge: How to Improve a Successful Gene Therapy Approach. <i>Molecular Therapy</i> , 2007, 15, 1248-1252.	8.2	131
97	The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. <i>Blood</i> , 2007, 109, 4708-4715.	1.4	200
98	Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. <i>Blood</i> , 2007, 109, 4698-4707.	1.4	171
99	Frequency and Targeted Detection of HLA-DPB1 T Cell Epitope Disparities Relevant in Unrelated Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1031-1040.	2.0	50
100	Therapeutic and Diagnostic Applications of Minor Histocompatibility Antigen HA-1 and HA-2 Disparities in Allogeneic Hematopoietic Stem Cell Transplantation: A Survey of Different Populations. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 95-101.	2.0	16
101	Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. <i>Blood</i> , 2006, 107, 1828-1836.	1.4	110
102	ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. <i>Journal of Biology</i> , 2006, 5, 14.	2.7	185
103	Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. <i>Nature Medicine</i> , 2006, 12, 1397-1402.	30.7	593
104	1107. Gene Therapy Clinical Trials for Relapsed Leukemia with Infusions of the Suicide-Gene Transduced Donor Lymphocytes in Japan. <i>Molecular Therapy</i> , 2006, 13, S426.	8.2	3
105	Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1457-1462.	7.1	172
106	Rapid and Wide Immunoreconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT. <i>Blood</i> , 2006, 108, 307-307.	1.4	4
107	Application of Donor Lymphocytes Expressing a Suicide Gene for Early GVL Induction and Later Control of GVH Reactions After Bone-Marrow Transplantation. , 2005, 109, 475-486.		8
108	Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. <i>Blood</i> , 2005, 105, 1162-1169.	1.4	435

#	ARTICLE	IF	CITATIONS
109	Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses. <i>Blood</i> , 2005, 105, 3596-3604.	1.4	15
110	Retrovirus mediated gene transduction of human T-cell subsets. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 759-768.	4.2	6
111	Transfection of RNA Encoding Tumor Antigens Following Maturation of Dendritic Cells Leads to Prolonged Presentation of Antigen and the Generation of High-Affinity Tumor-Reactive Cytotoxic T Lymphocytes. <i>Molecular Therapy</i> , 2004, 9, 757-764.	8.2	58
112	Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. <i>Blood</i> , 2003, 101, 1290-1298.	1.4	115
113	Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. <i>Blood</i> , 2003, 102, 497-505.	1.4	142
114	A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. <i>Blood</i> , 2003, 103, 1417-1424.	1.4	195
115	Targeting Antigen in Mature Dendritic Cells for Simultaneous Stimulation of CD4+and CD8+T Cells. <i>Journal of Immunology</i> , 2001, 166, 5250-5257.	0.8	101
116	A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. <i>Blood</i> , 2001, 97, 1249-1257.	1.4	59
117	Expression of HSV-TK suicide gene in primary T lymphocytes: The dog as a preclinical model. <i>Cytokines, Cellular & Molecular Therapy</i> , 2000, 6, 25-33.	0.3	10
118	Potential of Gene Therapy in Bone Marrow Transplantation. <i>BioDrugs</i> , 1999, 11, 1-6.	4.6	0
119	Herpes Simplex Virus Thymidine Kinase Gene Transfer for Controlled Graft-versus-Host Disease and Graft-versus-Leukemia: Clinical Follow-up and Improved New Vectors. <i>Human Gene Therapy</i> , 1998, 9, 2243-2251.	2.7	178
120	Transfer of the HSV-tk Gene into Donor Peripheral Blood Lymphocytes for In Vivo Modulation of Donor Anti-Tumor Immunity after Allogeneic Bone Marrow Transplantation. The San Raffaele Hospital, Milan, Italy. <i>Human Gene Therapy</i> , 1995, 6, 813-819.	2.7	137